BEVACIZUMAB Side Effects

7023200-3 | Amnesia, Chest Discomfort, Dyspnoea, Epistaxis, Eye Pain, Headache, Nail Disorder, Nasal Discomfort, Nausea
on Sep 21, 2010 Female patient from CANADA , weighting 110.2 lb, was diagnosed with blood pressure (What is blood pressure?), ulcer (What is ulcer?) and was treated with Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: amnesia, chest discomfort, dyspnoea, epistaxis, eye pain, headache (What is headache?), nail disorder, nasal discomfort, nausea (What is nausea?). Bevacizumab dosage: . During the same period patient was treated with ATENOLOL (View Atenolol Review and Atenolol Label ), PARIET (View Pariet Review and Pariet Label ), ACLASTA (View Aclasta Review and Aclasta Label ), SERAX (View Serax Review and Serax Label ). Patient was hospitalized.

7022499-7 | Acute Respiratory Distress Syndrome
Patient was taking Bevacizumab (View Usage). Patient had the following side effects: acute respiratory distress syndrome on Sep 23, 2010 from UNITED STATES Additional patient health information: Female patient , 80 years of age, . Bevacizumab dosage: Frequency: Over 30 To 90 Minutes On Day 1 And Day 15.. During the same period patient was treated with PACLITAXEL (Frequency: Over 30 Minutes On Days 1, 8 And 15, .last Dose Prior To Sae: 08 July 2010.) (View Paclitaxel Review and Paclitaxel Label ).

7022431-6 | Cataract, Eye Infection Staphylococcal
Adverse event was reported on Sep 20, 2010 by a Female patient taking Bevacizumab (View Usage) (Dosage: Dose:1.25 Mg/0.05 Ml.) . Location: UNITED STATES , 88 years of age, After Bevacizumab was administered, patient had the following side effects: cataract (What is cataract?), eye infection staphylococcal. During the same period patient was treated with GENTAMICIN (View Gentamicin Review and Gentamicin Label ).

7022413-4 | Deep Vein Thrombosis, Scrotal Abscess
on Sep 20, 2010 Male patient from GERMANY , weighting 145.5 lb, was treated with Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: deep vein thrombosis (What is deep vein thrombosis?), scrotal abscess. Bevacizumab dosage: . During the same period patient was treated with IRINOTECAN HCL (According To Folfiri Regimen) (View Irinotecan Hcl Review and Irinotecan Hcl Label ), FOLINIC ACID (According To Folfiri Regimen) (View Folinic Acid Review and Folinic Acid Label ), FLUOROURACIL (According To Folfiri Regimen) (View Fluorouracil Review and Fluorouracil Label ), ATROPIN (View Atropin Review and Atropin Label ), DEXA (View Dexa Review and Dexa Label ), KEVATRIL (View Kevatril Review and Kevatril Label ). Patient was hospitalized.


7022353-0 | Pyrexia
on Sep 21, 2010 Male patient from NETHERLANDS , weighting 203.9 lb, was diagnosed with metastatic renal cell carcinoma and was treated with Bevacizumab (View Usage). Patient had the following side effects: pyrexia. Bevacizumab dosage: Date Of Last Dose Prior To Sae:08 June 2010, Permanently Discontinued.. During the same period patient was treated with INTERFERON ALFA 2A (As Reported: Dose 3mie, Date Of Last Dose Prior To Sae: 16 June 2010, Permanently Discontinued.) (View Interferon Alfa-2a Review and Interferon Alfa-2a Label ), PARACETAMOL (View Paracetamol Review and Paracetamol Label ), TEOPTIC (View Teoptic Review and Teoptic Label ). Patient was hospitalized.

7020475-1 | Alanine Aminotransferase Increased
Patient was taking Bevacizumab (View Usage). After Bevacizumab was administered, patient had the following side effects: alanine aminotransferase increased on Sep 16, 2010 from UNITED STATES Additional patient health information: Female patient , weighting 185.2 lb, was diagnosed with ependymoma and. Bevacizumab dosage: . During the same period patient was treated with LAPATINIB (Dosing Amount: 1750 Mg) (View Lapatinib Review and Lapatinib Label ), LEVOTHYROXINE SODIUM (Reported As: Levothroxins Freq: Daily) (View Levothyroxine Sodium Review and Levothyroxine Sodium Label ), MULTI VITAMIN (Freq: Daily) (View Multi-vitamin Review and Multi-vitamin Label ), PROTONIX (Freq: Daily) (View Protonix Review and Protonix Label ), ASCORBIC ACID (Freq: Daily) (View Ascorbic Acid Review and Ascorbic Acid Label ).

7018157-5 | Asthenia, Febrile Neutropenia, Tuberculosis
Adverse event was reported on Sep 15, 2010 by a Female patient taking Bevacizumab (View Usage) (Dosage: Dosage Form Vials, Dose Level 15 Mg/kg) was diagnosed with breast cancer (What is breast cancer?), pulmonary tuberculosis and. Location: KOREA, REPUBLIC OF , weighting 99.21 lb, Patient experienced the following unwanted or unexpected effects: asthenia, febrile neutropenia, tuberculosis (What is tuberculosis?). During the same period patient was treated with TRASTUZUMAB (Loading Dose) (View Trastuzumab Review and Trastuzumab Label ), DOCETAXEL (Dosage Form: Vials, Dose:75 Mg/m2) (View Docetaxel Review and Docetaxel Label ), CARBOPLATIN (Dosage Form: Vials, Dose Level 6 Auc) (View Carboplatin Review and Carboplatin Label ), ISONIAZID (View Isoniazid Review and Isoniazid Label ), MYAMBUTOL (View Myambutol Review and Myambutol Label ), PYRAZINAMIDE (View Pyrazinamide Review and Pyrazinamide Label ), PIRIDOXINA (View Piridoxina Review and Piridoxina Label ). Patient was hospitalized.

7018152-6 | Panic Attack, Stomatitis
on Sep 23, 2010 Female patient from GERMANY , weighting 143.3 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Bevacizumab (View Usage). Patient had the following side effects: panic attack, stomatitis. Bevacizumab dosage: Frequency:on Day 1 + 21,dosage Form: Infusion., Last Dose Prior To Sae: 14 May 2010. During the same period patient was treated with EPIRUBICIN (Frequency: On Day 1 And 21, Dosage Form: I.v.) (View Epirubicin Review and Epirubicin Label ), CYCLOPHOSPHAMIDE (Frequency: On Day 1 And 21, Dosage Form: I.v.) (View Cyclophosphamide Review and Cyclophosphamide Label ), DOCETAXEL (Date Of Last Dose Prior To Sae: 14 May 2010) (View Docetaxel Review and Docetaxel Label ), CARBAMAZEPINE (View Carbamazepine Review and Carbamazepine Label ). Patient was hospitalized.

7018134-4 | Agitation, Confusional State, Convulsion, Neutropenia, Thrombocytopenia
on Sep 17, 2010 Female patient from UNITED STATES , weighting 180.8 lb, was diagnosed with glioblastoma and was treated with Bevacizumab (View Usage). After Bevacizumab was administered, patient had the following side effects: agitation, confusional state, convulsion, neutropenia, thrombocytopenia. Bevacizumab dosage: . During the same period patient was treated with TEMOZOLOMIDE (Frequency: Every Day) (View Temozolomide Review and Temozolomide Label ), KEPPRA (View Keppra Review and Keppra Label ), PANTOPRAZOLE SODIUM (Reported As Pantoprazolam) (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), CRESTOR (View Crestor Review and Crestor Label ), ASTEPRO (View Astepro Review and Astepro Label ), FLONASE (View Flonase Review and Flonase Label ), OXYCODONE (View Oxycodone Review and Oxycodone Label ), METOPROLOL TARTRATE (Eported As Medoprolol) (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ). Patient was hospitalized.

7018132-0 | Convulsion, Dyspnoea, Feeling Abnormal, Hypoaesthesia Oral, Malignant Neoplasm Progression, Muscle Spasms, Pain In Extremity, Skin Ulcer, Stomatitis
Patient was taking Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: convulsion, dyspnoea, feeling abnormal, hypoaesthesia oral, malignant neoplasm progression, muscle spasms, pain in extremity, skin ulcer, stomatitis on Sep 20, 2010 from CANADA Additional patient health information: Female patient , weighting 157.0 lb, was diagnosed with glioblastoma multiforme and. Bevacizumab dosage: Form: Infusion. During the same period patient was treated with DECADRON (View Decadron Review and Decadron Label ), MEDROXY (View Medroxy Review and Medroxy Label ). Patient was hospitalized.

7018112-5 | Renal Disorder
Adverse event was reported on Sep 20, 2010 by a Male patient taking Bevacizumab (View Usage) (Dosage: ) was diagnosed with prophylaxis, prophylaxis against gastrointestinal ulcer and. Location: UNITED STATES , weighting 178.6 lb, Patient had the following side effects: renal disorder. During the same period patient was treated with TEMSIROLIMUS (View Temsirolimus Review and Temsirolimus Label ), ATORVASTATINUM (View Atorvastatinum Review and Atorvastatinum Label ), CLONIDINE HYDROCHLORIDE (View Clonidine Hydrochloride Review and Clonidine Hydrochloride Label ), RAMIPRILUM (View Ramiprilum Review and Ramiprilum Label ), AMILORIDE HYDROCHLORIDE (View Amiloride Hydrochloride Review and Amiloride Hydrochloride Label ), OMEPRAZOLE (View Omeprazole Review and Omeprazole Label ).

7015231-4 | Anastomotic Fistula, Wernicke's Encephalopathy
on Sep 17, 2010 Male patient from FRANCE , weighting 163.1 lb, was diagnosed with rectal cancer and was treated with Bevacizumab (View Usage). After Bevacizumab was administered, patient had the following side effects: anastomotic fistula, wernicke's encephalopathy. Bevacizumab dosage: . During the same period patient was treated with FLUOROURACIL (Frequency: 5 Days Per Week, Date Of Last Dose Prior To Sae: 08 Jan 2010) (View Fluorouracil Review and Fluorouracil Label ), CORDARONE (View Cordarone Review and Cordarone Label ), ANTICOAGULANT NOS (View Anticoagulant Nos Review and Anticoagulant Nos Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), PREVISCAN (View Previscan Review and Previscan Label ). Patient was hospitalized.

7014692-4 | Deep Vein Thrombosis
on Jun 11, 2010 Female patient from SPAIN , 57 years of age, weighting 132.3 lb, was diagnosed with non-small cell lung cancer and was treated with Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: deep vein thrombosis (What is deep vein thrombosis?). Bevacizumab dosage: Frequency Reported As 21 Days. During the same period patient was treated with GEMCITABINA (Frequency Reported As 21 Days) (View Gemcitabina Review and Gemcitabina Label ), CISPLATIN (Frequency Reported As 21 Days) (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

7014632-8 | Tongue Oedema
Patient was taking Bevacizumab (View Usage). Patient had the following side effects: tongue oedema on Sep 19, 2010 from ITALY Additional patient health information: Male patient , weighting 224.9 lb, was diagnosed with non-small cell lung cancer and. Bevacizumab dosage: Form As Per Protocol: Vial For Infusion. Last Dose Prior To Sae 05 August 2010.. During the same period patient was treated with ALIMTA (Form:infusion. Last Dose Prior To Sae 05 August 2010.) (View Alimta Review and Alimta Label ), ZESTRIL (View Zestril Review and Zestril Label ). Patient was hospitalized.

7014616-X | Arthralgia, Asthenia, Decreased Appetite, Dyspnoea, Fatigue, Gait Disturbance, Haemoglobin Decreased, Influenza, Nasal Dryness
Adverse event was reported on Sep 17, 2010 by a Female patient taking Bevacizumab (View Usage) (Dosage: Form: Infusion) was diagnosed with breast cancer (What is breast cancer?), pain (What is pain?) and. Location: CANADA , weighting 145.5 lb, After Bevacizumab was administered, patient had the following side effects: arthralgia, asthenia, decreased appetite, dyspnoea, fatigue, gait disturbance, haemoglobin decreased, influenza, nasal dryness. During the same period patient was treated with CAPECITABINE (View Capecitabine Review and Capecitabine Label ), MORPHINE (View Morphine Review and Morphine Label ). Patient was hospitalized.

7014614-6 | Ileus, Implant Site Necrosis
on Sep 17, 2010 Female patient from FRANCE , weighting 134.5 lb, was treated with Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: ileus, implant site necrosis. Bevacizumab dosage: Date Of Last Dose Prior To Sae: 27 April 2010. During the same period patient was treated with DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ). Patient was hospitalized.

7014608-0 | Pericardial Effusion
on Sep 23, 2010 Male patient from FRANCE , weighting 169.8 lb, was diagnosed with non-small cell lung cancer and was treated with Bevacizumab (View Usage). Patient had the following side effects: pericardial effusion. Bevacizumab dosage: Form: Infusion. Last Dose Prior To Sae 20 April 2010. Dose: 575 Mg.. During the same period patient was treated with CISPLATIN (Form: Infusion.last Dose Prior To Sae: 20 Apr 2010. Dosage Form: Unkown.) (View Cisplatin Review and Cisplatin Label ), PEMETREXED (Form: Infusion. Last Dose Prior To Sae: 20 Apr 2010.) (View Pemetrexed Review and Pemetrexed Label ), LYTOS (View Lytos Review and Lytos Label ), VOLTAREN (View Voltaren Review and Voltaren Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ), TOPALGIC (View Topalgic Review and Topalgic Label ), EFFEXOR (View Effexor Review and Effexor Label ), MIANSERINE (View Mianserine Review and Mianserine Label ). Patient was hospitalized.

7014605-5 | Arthralgia, Dehydration, Fatigue, Hypokalaemia, Hypophosphataemia, Mucosal Inflammation
Patient was taking Bevacizumab (View Usage). After Bevacizumab was administered, patient had the following side effects: arthralgia, dehydration, fatigue, hypokalaemia, hypophosphataemia, mucosal inflammation on Sep 15, 2010 from UNITED STATES Additional patient health information: Female patient , 75 years of age, weighting 170.4 lb, . Bevacizumab dosage: Frequency:over 30-90 Minutes On Day 1 And 15.last Dose Of Prior To Sae:26 April 2010(cycle1, Day15). During the same period patient was treated with TEMSIROLIMUS (Frequency:over 30 Minutes On Day 1,8,15 And22.last Dose Of Prior To Sae: 03 May 2010 (cycle1,day22)) (View Temsirolimus Review and Temsirolimus Label ). Patient was hospitalized.

7014595-5 | Cardiac Failure Congestive, Pulmonary Embolism
Adverse event was reported on Sep 21, 2010 by a Male patient taking Bevacizumab (View Usage) (Dosage: ) was diagnosed with non-small cell lung cancer and. Location: SPAIN , weighting 198.4 lb, Patient experienced the following unwanted or unexpected effects: cardiac failure congestive, pulmonary embolism (What is pulmonary embolism?). During the same period patient was treated with ERLOTINIB HYDROCHLORIDE (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ), CAPTOPIRIL (Reported As Captoprilo Start Date: 2008) (View Captopiril Review and Captopiril Label ). Patient was hospitalized.

7013350-X | Masked Facies, Movement Disorder, Myocardial Ischaemia, Palpitations, Paraneoplastic Syndrome, Pulmonary Fibrosis, Pulmonary Hypertension, Raynaud's Phenomenon, Restrictive Pulmonary Disease
on Sep 15, 2010 Female patient from JAPAN , weighting 116.8 lb, was diagnosed with breast cancer metastatic, malaise, oedema and was treated with Bevacizumab (View Usage). Patient had the following side effects: masked facies, movement disorder (What is movement disorder?), myocardial ischaemia, palpitations, paraneoplastic syndrome, pulmonary fibrosis (What is pulmonary fibrosis?), pulmonary hypertension (What is pulmonary hypertension?), raynaud's phenomenon, restrictive pulmonary disease. Bevacizumab dosage: Route: Intravenous (not Otherwise Specified). During the same period patient was treated with PACLITAXEL (Route: Intravenous (not Otherwise Specified)) (View Paclitaxel Review and Paclitaxel Label ), RINDERON (View Rinderon Review and Rinderon Label ), LASIX (View Lasix Review and Lasix Label ), FEMARA (View Femara Review and Femara Label ), ZOLADEX (View Zoladex Review and Zoladex Label ), KETOPROFEN (View Ketoprofen Review and Ketoprofen Label ), MOMETASONE FUROATE (View Mometasone Furoate Review and Mometasone Furoate Label ), DORNER (View Dorner Review and Dorner Label ).

7013334-1 | Cardiogenic Shock, Mucosal Inflammation
on Sep 23, 2010 Female patient from GERMANY , weighting 145.9 lb, was diagnosed with non-small cell lung cancer and was treated with Bevacizumab (View Usage). After Bevacizumab was administered, patient had the following side effects: cardiogenic shock, mucosal inflammation. Bevacizumab dosage: Form: Liquid, Last Dose Prior To Sae: 13 May 2010, Once. During the same period patient was treated with PEMETREXED (Form: Liquid, Last Dose Prior To Sae: 13 May 2010. Once) (View Pemetrexed Review and Pemetrexed Label ), CISPLATIN (Form: Liquid, Last Dose Prior To Sae: 13 May 2010, Once) (View Cisplatin Review and Cisplatin Label ), SYMBICORT (View Symbicort Review and Symbicort Label ), SALBUTAMOL (Prn) (View Salbutamol Review and Salbutamol Label ), RAMIPRIL (View Ramipril Review and Ramipril Label ), TRI THIAZID (View Tri-thiazid Review and Tri-thiazid Label ), FELODIPINE (View Felodipine Review and Felodipine Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ).

7012714-8 | Cerebral Haemorrhage, Haemangioma, Lower Extremity Mass, Pain In Extremity
Patient was taking Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: cerebral haemorrhage, haemangioma, lower extremity mass, pain in extremity on Sep 13, 2010 from GERMANY Additional patient health information: Female patient , weighting 143.7 lb, was diagnosed with bronchial carcinoma and. Bevacizumab dosage: The 6th Cycle Started On 21-apr-2010. During the same period patient was treated with PACLITAXEL (The 6th Cycle Started On 21-apr-2010) (View Paclitaxel Review and Paclitaxel Label ), CARBOPLATIN (The 6th Cycle Started On 21-apr-2010) (View Carboplatin Review and Carboplatin Label ).

7012703-3 | Empyema, Malignant Neoplasm Progression, Pneumonia, Wound Dehiscence
Adverse event was reported on Sep 14, 2010 by a Male patient taking Bevacizumab (View Usage) (Dosage: ) was diagnosed with lung adenocarcinoma and. Location: UNITED STATES , 83 years of age, weighting 181.9 lb, Patient had the following side effects: empyema, malignant neoplasm progression, pneumonia (What is pneumonia?), wound dehiscence. During the same period patient was treated with ERLOTINIB HYDROCHLORIDE (Total Dose Administered This Course: 2550 Mg, Last Administered Date: 09 Spetember 2010, Cycle 20) (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ). Patient was hospitalized.

7012670-2 | Agitation, Confusional State, Convulsion, Thrombocytopenia
on Sep 14, 2010 Female patient from UNITED STATES , weighting 180.8 lb, was diagnosed with glioblastoma and was treated with Bevacizumab (View Usage). After Bevacizumab was administered, patient had the following side effects: agitation, confusional state, convulsion, thrombocytopenia. Bevacizumab dosage: . During the same period patient was treated with TEMOZOLOMIDE (Frequency: Every Day) (View Temozolomide Review and Temozolomide Label ), KEPPRA (View Keppra Review and Keppra Label ), PANTOPRAZOLE SODIUM (Reported As Pantoprazolam) (View Pantoprazole Sodium Review and Pantoprazole Sodium Label ), CRESTOR (View Crestor Review and Crestor Label ), ASTEPRO (View Astepro Review and Astepro Label ), FLONASE (View Flonase Review and Flonase Label ), OXYCODONE (View Oxycodone Review and Oxycodone Label ), METOPROLOL TARTRATE (Eported As Medoprolol) (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ). Patient was hospitalized.

7012668-4 | Neutropenia, Thrombocytopenia, Transaminases Increased
on Sep 14, 2010 Female patient from UNITED STATES , weighting 155.2 lb, was diagnosed with glioblastoma and was treated with Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: neutropenia, thrombocytopenia, transaminases increased. Bevacizumab dosage: . During the same period patient was treated with IRINOTECAN HCL (View Irinotecan Hcl Review and Irinotecan Hcl Label ), TEMOZOLOMIDE (View Temozolomide Review and Temozolomide Label ), DECADRON (View Decadron Review and Decadron Label ), CALCIUM (View Calcium Review and Calcium Label ), ERGOCALCIFEROL (View Ergocalciferol Review and Ergocalciferol Label ), DILANTIN (View Dilantin Review and Dilantin Label ). Patient was hospitalized.

7012643-X | Dehydration, Failure To Thrive, Nausea, Syncope, Thrombosis, Urine Electrolytes Decreased, Weight Decreased
Patient was taking Bevacizumab (View Usage). Patient had the following side effects: dehydration, failure to thrive, nausea (What is nausea?), syncope, thrombosis, urine electrolytes decreased, weight decreased on Sep 10, 2010 from UNITED STATES Additional patient health information: Male patient , 52 years of age, weighting 249.3 lb, . Bevacizumab dosage: Last Treatment On 6 June 2010. Dose 15 Mg/kg, Frequency Reported Day 1.. During the same period patient was treated with CETUXIMAB (Last Treatment On 6 June 2010, Dose 250 Mg/m2 Frequency Day 1.) (View Cetuximab Review and Cetuximab Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), OXYCODONE (Frequency: Q4) (View Oxycodone Review and Oxycodone Label ), REGLAN (Frequency: Bo) (View Reglan Review and Reglan Label ). Patient was hospitalized.

7012635-0 | Cholecystitis, Cholecystitis Acute
Adverse event was reported on Sep 15, 2010 by a Female patient taking Bevacizumab (View Usage) (Dosage: Cycle: 28 Days, Frequency: Over 30-90 Min Onn Days 1 And 15, Last Dose Prioe To Sae: 04 June 2010) was diagnosed with breast cancer (What is breast cancer?) and. Location: UNITED STATES , 57 years of age, weighting 109.6 lb, After Bevacizumab was administered, patient had the following side effects: cholecystitis, cholecystitis acute. During the same period patient was treated with IXABEPILONE (Frequency: Over 1 Hour On Days 1, 8 And 15. Last Dose Prior Sae On 04 June 2010) (View Ixabepilone Review and Ixabepilone Label ).

7012632-5 | Renal Failure Acute, Septic Shock
on Sep 21, 2010 Male patient from FRANCE , weighting 176.4 lb, was diagnosed with non-small cell lung cancer and was treated with Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: renal failure acute, septic shock. Bevacizumab dosage: Last Dose Prior To Sae On 01 December 09, Form: Vial. During the same period patient was treated with PEMETREXED (Last Dose Prior To Sae On 01 Dec 09, Form: Vial) (View Pemetrexed Review and Pemetrexed Label ), CISPLATIN (Last Dose Prior To Sae On 01 Dec 09, Form: Vial) (View Cisplatin Review and Cisplatin Label ), VERAPAMIL (View Verapamil Review and Verapamil Label ), ATORVASTATIN CALCIUM (View Atorvastatin Calcium Review and Atorvastatin Calcium Label ), ESOMEPRAZOLE MAGNESIUM (View Esomeprazole Magnesium Review and Esomeprazole Magnesium Label ), EZETIMIBE (View Ezetimibe Review and Ezetimibe Label ), GLICLAZIDE (View Gliclazide Review and Gliclazide Label ), BIGUANIDES (View Biguanides Review and Biguanides Label ). Patient was hospitalized.

7012631-3 | Convulsion, Interstitial Lung Disease, Pneumonitis
on Sep 10, 2010 Female patient from UNITED STATES , weighting 117.9 lb, was diagnosed with glioblastoma multiforme, anxiety (What is anxiety?) and was treated with Bevacizumab (View Usage). Patient had the following side effects: convulsion, interstitial lung disease, pneumonitis. Bevacizumab dosage: 454 Mg, Unk. During the same period patient was treated with TEMODAR (115 Mg, Unk) (View Temodar Review and Temodar Label ), EVEROLIMUS (10 Mg, Qd) (View Everolimus Review and Everolimus Label ), ATIVAN (Frequency: Prn) (View Ativan Review and Ativan Label ), XANAX (View Xanax Review and Xanax Label ), MORPHINE (View Morphine Review and Morphine Label ). Patient was hospitalized.

7010846-1 | Epistaxis, Headache, Hypertension, Malignant Neoplasm Progression
Patient was taking Bevacizumab (View Usage). After Bevacizumab was administered, patient had the following side effects: epistaxis, headache (What is headache?), hypertension, malignant neoplasm progression on Sep 23, 2010 from UNITED STATES Additional patient health information: Male patient , 59 years of age, weighting 185.8 lb, was diagnosed with oesophageal cancer metastatic and. Bevacizumab dosage: 10mg/kg Q 3 Weeks. During the same period patient was treated with CISPLATIN (30mg/m2 D1d8qcyc) (View Cisplatin Review and Cisplatin Label ), IRINOTECAN HCL (65mg/m2 D1d8qcyc) (View Irinotecan Hcl Review and Irinotecan Hcl Label ), AMLODIPINE (View Amlodipine Review and Amlodipine Label ), ATENOLOL (View Atenolol Review and Atenolol Label ), BACLOFEN (View Baclofen Review and Baclofen Label ), PROCHLORPERAZINE MALEATE (View Prochlorperazine Maleate Review and Prochlorperazine Maleate Label ), DIPHENOXYLATE W/ATROPINE GTUBE (View Diphenoxylate W/atropine Gtube Review and Diphenoxylate W/atropine Gtube Label ), KETOCONAZOLE GEL (View Ketoconazole Gel Review and Ketoconazole Gel Label ). Patient was hospitalized.

7009803-0 | Abdominal Pain, Amnesia, Aphasia, Balance Disorder, Chest Pain, Convulsion, Cough, Dizziness, Muscle Twitching
Adverse event was reported on Sep 13, 2010 by a Male patient taking Bevacizumab (View Usage) (Dosage: Form: Infusion, Other Indication: Glioblastoma.) was diagnosed with metastatic malignant melanoma and. Location: CANADA , weighting 179.9 lb, Patient experienced the following unwanted or unexpected effects: abdominal pain (What is abdominal pain?), amnesia, aphasia (What is aphasia?), balance disorder, chest pain (What is chest pain?), convulsion, cough, dizziness (What is dizziness?), muscle twitching. During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ), DILANTIN (View Dilantin Review and Dilantin Label ), NEXIUM (View Nexium Review and Nexium Label ), TYLENOL (View Tylenol Review and Tylenol Label ), OXAZEPAM (View Oxazepam Review and Oxazepam Label ), METOCLOPRAMIDE (View Metoclopramide Review and Metoclopramide Label ), RANITIDINE (View Ranitidine Review and Ranitidine Label ), LORAZEPAM (View Lorazepam Review and Lorazepam Label ). Patient was hospitalized.

7009785-1 | Cardiogenic Shock, Mucosal Inflammation
on Sep 20, 2010 Female patient from GERMANY , weighting 145.9 lb, was diagnosed with non-small cell lung cancer and was treated with Bevacizumab (View Usage). Patient had the following side effects: cardiogenic shock, mucosal inflammation. Bevacizumab dosage: Form: Liquid, Last Dose Prior To Sae: 13 May 2010, Once. During the same period patient was treated with PEMETREXED (Form: Liquid, Last Dose Prior To Sae: 13 May 2010. Once) (View Pemetrexed Review and Pemetrexed Label ), CISPLATIN (Form: Liquid, Last Dose Prior To Sae: 13 May 2010, Once) (View Cisplatin Review and Cisplatin Label ), SYMBICORT (View Symbicort Review and Symbicort Label ), SALBUTAMOL (Prn) (View Salbutamol Review and Salbutamol Label ), RAMIPRIL (View Ramipril Review and Ramipril Label ), TRI THIAZID (View Tri-thiazid Review and Tri-thiazid Label ), FELODIPINE (View Felodipine Review and Felodipine Label ), METOPROLOL TARTRATE (View Metoprolol Tartrate Review and Metoprolol Tartrate Label ).

7007852-X | Anaemia
on Sep 13, 2010 Female patient from BELGIUM , 79 years of age, was treated with Bevacizumab (View Usage). After Bevacizumab was administered, patient had the following side effects: anaemia. Bevacizumab dosage: . During the same period patient was treated with FOLINIC ACID (Reported As; Folfiri) (View Folinic Acid Review and Folinic Acid Label ), FLUOROURACIL (Reported As; Folfiri) (View Fluorouracil Review and Fluorouracil Label ), IRINOTECAN HCL (Reported As; Folfiri) (View Irinotecan Hcl Review and Irinotecan Hcl Label ).

7007841-5 | Macular Oedema
Patient was taking Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: macular oedema on Sep 14, 2010 from UNITED STATES Additional patient health information: Female patient , 58 years of age, . Bevacizumab dosage: . During the same period patient was treated with ABRAXANE (View Abraxane Review and Abraxane Label ).

7007811-7 | Nausea, Vertigo
Adverse event was reported on Sep 11, 2010 by a Male patient taking Bevacizumab (View Usage) (Dosage: ) was diagnosed with non-small cell lung cancer, prophylaxis, insomnia and. Location: GERMANY , weighting 158.7 lb, Patient had the following side effects: nausea (What is nausea?), vertigo. During the same period patient was treated with PEMETREXED (View Pemetrexed Review and Pemetrexed Label ), CISPLATIN (Last Dose Prior To Sae: 28 July 2010.) (View Cisplatin Review and Cisplatin Label ), FOLIC ACID (View Folic Acid Review and Folic Acid Label ), CYANOCOBALAMIN (View Cyanocobalamin Review and Cyanocobalamin Label ), DEXAMETASONE (View Dexametasone Review and Dexametasone Label ), ZOPICLONE (View Zopiclone Review and Zopiclone Label ). Patient was hospitalized.

7007793-8 | Pyrexia
on Sep 14, 2010 Male patient from NETHERLANDS , weighting 203.9 lb, was diagnosed with metastatic renal cell carcinoma and was treated with Bevacizumab (View Usage). After Bevacizumab was administered, patient had the following side effects: pyrexia. Bevacizumab dosage: Date Of Last Dose Prior To Sae:08 June 2010, Permanently Discontinued.. During the same period patient was treated with INTERFERON ALFA 2A (As Reported: Dose 3mie, Date Of Last Dose Prior To Sae: 16 June 2010, Permanently Discontinued.) (View Interferon Alfa-2a Review and Interferon Alfa-2a Label ), ACETAMINOPHEN (View Acetaminophen Review and Acetaminophen Label ). Patient was hospitalized.

7007790-2 | Palmar-plantar Erythrodysaesthesia Syndrome
on Sep 13, 2010 Female patient from GERMANY , weighting 163.1 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: palmar-plantar erythrodysaesthesia syndrome. Bevacizumab dosage: Date Of Last Dose Prior To Sae: 17 May 2010. During the same period patient was treated with DOCETAXEL (Date Of Last Dose Prior To Sae: 17 May 2010) (View Docetaxel Review and Docetaxel Label ), EPIRUBICIN (Date Of Last Dose Prior To Sae: 22 February 2010) (View Epirubicin Review and Epirubicin Label ), CYCLOPHOSPHAMIDE (Date Of Last Dose Prior To Sae: 22 February 2010) (View Cyclophosphamide Review and Cyclophosphamide Label ).

7005478-5 | Cystitis Viral
Patient was taking Bevacizumab (View Usage). Patient had the following side effects: cystitis viral on Sep 09, 2010 from GERMANY Additional patient health information: Female patient , weighting 180.3 lb, was diagnosed with antiemetic supportive care and. Bevacizumab dosage: 3rd Cycle. During the same period patient was treated with FOLINIC ACID (3rd Cycle) (View Folinic Acid Review and Folinic Acid Label ), FLUOROURACIL (3rd Cycle) (View Fluorouracil Review and Fluorouracil Label ), KEVATRIL (View Kevatril Review and Kevatril Label ), VERGENTAN (View Vergentan Review and Vergentan Label ), DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ). Patient was hospitalized.

7005471-2 | Convulsion, Dyspnoea, Feeling Abnormal, Hypoaesthesia Oral, Muscle Spasms, Pain In Extremity, Skin Ulcer, Stomatitis, White Blood Cell Count Abnormal
Adverse event was reported on Sep 10, 2010 by a Female patient taking Bevacizumab (View Usage) (Dosage: Form: Infusion) was diagnosed with glioblastoma multiforme and. Location: CANADA , weighting 157.0 lb, After Bevacizumab was administered, patient had the following side effects: convulsion, dyspnoea, feeling abnormal, hypoaesthesia oral, muscle spasms, pain in extremity, skin ulcer, stomatitis, white blood cell count abnormal. During the same period patient was treated with DECADRON (View Decadron Review and Decadron Label ), MEDROXY (View Medroxy Review and Medroxy Label ).

7005465-7 | Altered State Of Consciousness, Hyperammonaemia
on Sep 10, 2010 Male patient from JAPAN , 67 years of age, was diagnosed with large intestine carcinoma and was treated with Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: altered state of consciousness, hyperammonaemia. Bevacizumab dosage: . During the same period patient was treated with ELPLAT (Note: Dosage Is Uncertain) (View Elplat Review and Elplat Label ), LEUCOVORIN CALCIUM (Note: Dosage Is Uncertain) (View Leucovorin Calcium Review and Leucovorin Calcium Label ), FLUOROURACIL (Route: Intravenous Drip. Note: Dosage Is Uncertain) (View Fluorouracil Review and Fluorouracil Label ). Patient was hospitalized.

7005433-5 | Convulsion
on Sep 13, 2010 Female patient from TURKEY , 50 years of age, weighting 165.3 lb, was diagnosed with rectal cancer metastatic and was treated with Bevacizumab (View Usage). Patient had the following side effects: convulsion. Bevacizumab dosage: Form And Frequency: Not Reported.. During the same period patient was treated with IRINOTECAN HCL (Frequency: Not Reported.) (View Irinotecan Hcl Review and Irinotecan Hcl Label ), FLUOROURACIL (Frequency: Not Reported.) (View Fluorouracil Review and Fluorouracil Label ).

7005428-1 | Constipation, Neoplasm Recurrence
Patient was taking Bevacizumab (View Usage). After Bevacizumab was administered, patient had the following side effects: constipation (What is constipation?), neoplasm recurrence on Sep 10, 2010 from CANADA Additional patient health information: Female patient , weighting 112.4 lb, was diagnosed with oligodendroglioma and. Bevacizumab dosage: . During the same period patient was treated with TEGRETOL (View Tegretol Review and Tegretol Label ), CLONAZEPAM (View Clonazepam Review and Clonazepam Label ), PANTOLOC (View Pantoloc Review and Pantoloc Label ), TEMODAL (View Temodal Review and Temodal Label ).

7005424-4 | Anaemia, Granulocytopenia, Leukopenia, Neutropenia, Pneumonia, Pyothorax, Thrombocytopenia
Adverse event was reported on Sep 14, 2010 by a Male patient taking Bevacizumab (View Usage) (Dosage: Frequency: 1x, Form Infusion;) was diagnosed with non-small cell lung cancer and. Location: HUNGARY , weighting 158.7 lb, Patient experienced the following unwanted or unexpected effects: anaemia, granulocytopenia, leukopenia, neutropenia, pneumonia (What is pneumonia?), pyothorax, thrombocytopenia. During the same period patient was treated with GEMCITABINE (Form Infusion, On Day 1 And Day 8; Frequency: 1xdaily;) (View Gemcitabine Review and Gemcitabine Label ). Patient was hospitalized.

7005405-0 | Epistaxis, Haematochezia
on Sep 09, 2010 Female patient from HUNGARY , weighting 136.7 lb, was diagnosed with non-small cell lung cancer and was treated with Bevacizumab (View Usage). Patient had the following side effects: epistaxis, haematochezia. Bevacizumab dosage: Frequency:cycle, Last Dose Prior To Sae 10 February 2010; Form: Infusion.. During the same period patient was treated with GEMCITABINE (Frequency: 1 Day-8 Day, Last Dose Prior To Sae 10 February 2010) (View Gemcitabine Review and Gemcitabine Label ), CARBOPLATIN (Frequency:1 Day, Last Dose Prior To Sae 10 February 2010) (View Carboplatin Review and Carboplatin Label ), ONDANSETRON (View Ondansetron Review and Ondansetron Label ), APREPITANT (View Aprepitant Review and Aprepitant Label ), EPOGEN (View Epogen Review and Epogen Label ). Patient was hospitalized.

7005386-X | Diarrhoea, Mucosal Inflammation, Neutropenia, Renal Failure
on Sep 16, 2010 Male patient from SPAIN , weighting 176.4 lb, was diagnosed with non-small cell lung cancer and was treated with Bevacizumab (View Usage). After Bevacizumab was administered, patient had the following side effects: diarrhoea, mucosal inflammation, neutropenia, renal failure. Bevacizumab dosage: . During the same period patient was treated with PEMETREXED (View Pemetrexed Review and Pemetrexed Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ). Patient was hospitalized.

7001503-6 | Speech Disorder
Patient was taking Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: speech disorder on Sep 14, 2010 from UNITED STATES Additional patient health information: Male patient , 83 years of age, weighting 145.9 lb, was diagnosed with lung adenocarcinoma and. Bevacizumab dosage: Last Dose Prior Sae: 26 August 2010. During the same period patient was treated with ERLOTINIB HYDROCHLORIDE (View Erlotinib Hydrochloride Review and Erlotinib Hydrochloride Label ), CARDURA (View Cardura Review and Cardura Label ), LEXAPRO (View Lexapro Review and Lexapro Label ), DULCOLAX (View Dulcolax Review and Dulcolax Label ), IBUPROFEN (View Ibuprofen Review and Ibuprofen Label ), NOVOLOG (Reported As Novalog) (View Novolog Review and Novolog Label ), SALMETEROL (View Salmeterol Review and Salmeterol Label ), SIMVASTATIN (View Simvastatin Review and Simvastatin Label ). Patient was hospitalized.

7001489-4 | Asthenia, Decreased Appetite, Dry Mouth, Haematotoxicity, Nausea
Adverse event was reported on Sep 12, 2010 by a Male patient taking Bevacizumab (View Usage) (Dosage: Dose: 380 Mg Absolute) . Location: AUSTRIA , 78 years of age, Patient had the following side effects: asthenia, decreased appetite, dry mouth, haematotoxicity, nausea (What is nausea?). During the same period patient was treated with FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), FOLINIC ACID (View Folinic Acid Review and Folinic Acid Label ), OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ). Patient was hospitalized.

7001483-3 | Urinary Retention
on Sep 08, 2010 Female patient from CHINA , weighting 348.3 lb, was diagnosed with breast cancer (What is breast cancer?) and was treated with Bevacizumab (View Usage). After Bevacizumab was administered, patient had the following side effects: urinary retention. Bevacizumab dosage: Form: Vials, Total Dose: 1000 Mg, Last Dose Prior To Sae: 19 August 2010. During the same period patient was treated with TRASTUZUMAB (Form:vials, Loading Dose) (View Trastuzumab Review and Trastuzumab Label ), CARBOPLATIN (Form:vials,dose Level: 6 Auc, Date Of Last Dose Prior To Sae: 19 August 2010) (View Carboplatin Review and Carboplatin Label ), DOCETAXEL (Form:vials, Total Dose:128 Mg, Date Of Last Dose Prior To Sae: 19 August 2010) (View Docetaxel Review and Docetaxel Label ). Patient was hospitalized.

7001482-1 | Abdominal Pain Upper, Back Pain, Gait Disturbance, Muscle Spasms, Neuropathy Peripheral, Pubis Fracture
on Sep 09, 2010 Male patient from UNITED STATES , weighting 350.5 lb, was diagnosed with metastatic carcinoid tumour and was treated with Bevacizumab (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal pain upper, back pain (What is back pain?), gait disturbance, muscle spasms, neuropathy peripheral, pubis fracture. Bevacizumab dosage: . During the same period patient was treated with LEUCOVORIN CALCIUM (View Leucovorin Calcium Review and Leucovorin Calcium Label ), FLUOROURACIL (View Fluorouracil Review and Fluorouracil Label ), OXALIPLATIN (View Oxaliplatin Review and Oxaliplatin Label ). Patient was hospitalized.

7001480-8 | Febrile Bone Marrow Aplasia
Patient was taking Bevacizumab (View Usage). Patient had the following side effects: febrile bone marrow aplasia on Sep 09, 2010 from FRANCE Additional patient health information: Male patient , weighting 143.3 lb, was diagnosed with non-small cell lung cancer and. Bevacizumab dosage: Last Dose Pror To Sae: 02 September 2010. During the same period patient was treated with PACLITAXEL (Last Dose Prior To Sae: 02 Sep 2010) (View Paclitaxel Review and Paclitaxel Label ), CARBOPLATIN (Dose: 6 Auc. Last Dose Prior To Sae: 02 Sep 2010.) (View Carboplatin Review and Carboplatin Label ). Patient was hospitalized.